Senior Med Affairs Professional/ Formerly GSK, SVP Global Medical Affairs
Danie is a senior pharmaceutical executive with 25 years’ experience mainly in medical affairs. He has a passion for modernising medical affairs and track record in leadership, people development, capability building and coaching. Danie is a qualified MD with a Masters in Clinical Pharmacology who combines medical and life science qualifications with an MBA. Danie has extensive experience building international teams, driving change and working in regulated markets for GlaxoSmithKline (GSK) across Europe, the Americas, Middle East, Africa, Australasia and Japan.He previously worked for Eli Lilly & Company for 17 years in different medical roles as well as marketing and sales. During his different roles, he was based in South Africa, United Kingdom and Australia. Before joining the Pharmaceutical Industry, Danie had his own primary care practice. Danie started his own mentoring, coaching and consulting business, TheNextVersion Ltd, in Jul 2018.
Former Medical Director and Head of Medical Affairs (Russia) / Boehringer-Ingelheim
Alexandra Safronova, MD is currently Medical Director and Head of Medical Affairs at Boehringer-Ingelheim, Russia.
Dr. Safronova earned her medical degree from Moscow Medical Academy cum laude. She completed her residency in internal medicine at Moscow Medical Academy, and fellowships in intensive care at Pirogov Medical University and endocrinology at the Russian Medical Postgraduate Academy.
Before her pharmaceutical career, Dr. Safronova served as a staff physician in the Cardiology and Intensive Care Department at Medical Center of the Russian Academy of Science.
Dr. Safronova started her career in the pharmaceutical industry in 1999 as Clinical Research Scientist at GlaxoSmithKline, then she worked as Manager of Clinical Operations at Quintiles (now IQVIA).
In 2010 she joined Teva as Director of Clinical Research. Her primary task there was to set up Clinical Research Department from the scratch to support registration of new products and supervise global studies. Within two years Teva became #1 in clinical research in Russia. The company received 7 new market authorizations supported by the results of clinical program developed and executed by the department headed by Dr. Safronova. In 2013 Dr Safonova focused on building Medical Affairs function as Medical Director of Russia and CIS, Teva Pharmaceutical.
Dr. Safronova’s experience in multiple therapeutic areas includes Phases I-IV and diverse disciplines of medical affairs and product commercialization, such as leading office based and field-based medical teams (MSLs), PV/safety, Regulatory Affairs, Medical information, Patient Advocacy.
Malcolm is Managing Director, of PharmaMedic Consultancy Ltd a London based International biosciences consultancy company, and Immediate Past President of the Section of Pharmaceutical Medicine and Research of The Royal Society of Medicine, London, UK.
With over 20 years experience as a Consultant Pharmaceutical Physician to Industry and Government, Malcolm advises bioscience and pharmaceutical companies on Product Development, Regulatory Strategy and Medical Affairs, focusing on Start-Ups and SMEs. He acts as a Clinical Specialist and Chair to the European Commission’s Biomedical Research Programme (Horizon 2020), lectures in both Europe and the United States on medicinal development, and teaches on the Pharmaceutical Medicine and Regulatory MSc Course of Copenhagen University.
Following a first degree in Physiology at King’s College London, Malcolm qualified in medicine from St Bartholomew’s Hospital, in 1993. After postgraduate training in General and Intensive Care Medicine he joined the UK Government as a Medical Assessor in new medicines in 1997. After senior industry roles at Pfizer and AstraZeneca he re-joined Government as Lead Medical Assessor to the UK Dept of Health’s Clinical Trials Unit on it’s formation in 2005, and worked with the European Medicines Agency (EMA) on the development of a trans-European clinical development process in the pharma and biotech sectors. Leaving full time employment with the Government in February 2007, Malcolm was appointed as an Independent Consultant to the Dept of Health.
He has worked extensively in senior UK and Global consultancy positions with most of the top ten pharma companies including AstraZeneca, Eisai, Roche, Novartis, Schering-Plough / MSD and GSK, in addition to having advisory development roles in the biotech, device and generic pharma sectors.
In 2012 he was appointed President to the Section of Pharmaceutical Medicine and Research at the Royal Society of Medicine, London and in 2014, a Fellow of The Royal Society of Biology.
Vice President, Global Medical Affairs Services / Ipsen Pharma SA
Dr Mónica de Abadal is an Executive Leadership Committee Member of the Medical Affairs Professional Society EMEA with more than 16 years of experience in the pharmaceutical industry
Dr de Abadal has experience in multiple therapeutic areas, including oncology, endocrinology and movement disorders as well as operational and strategic Medical Affairs experience in diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, quality management systems, data generation, field-based medical teams (MSLs), safety, medical communication & publications
She has served as a board member in companies specialized in telemedicine and has international Medical Affairs experience in Europe, APAC (Australia) and global positions, including deputy Chief Medical Officer, Global Head of Publications. She currently holds the VP Global Medical Affairs Services group position at Ipsen.
Dr de Abadal obtained her medical degree from the University of Barcelona and entered residency in Anaesthesiology in Hospital Vall d´Hebron (Barcelona) ). She validated her medical degree in the US (USMLE) and obtained an MBA specialized in Healthcare administration from (USF) and a postgraduate diploma in Pharmaceutical Medicine (UAB).
She feels passionate about Medical Excellence.
(MAPS President) / EVP and Head of Medical Affairs / Astellas Pharma
Charlotte M. E. Kremer, MD, MBA is the Executive VP and head of Medical Affairs for Astellas. In this role, Dr. Kremer provides leadership for the Medical Affairs organization globally.
Dr. Kremer joined Astellas in 2012 with 20 years of experience in the pharmaceutical industry. Prior to Astellas, she held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer. While at Pfizer, she successfully led and executed the clinical development and global medical programs in these respective areas. Prior to joining Pfizer, Dr. Kremer held positions of increasing responsibility providing medical support, developing Phase 3b/4 clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States. A native of the Netherlands, Dr. Kremer received her medical degree from the University of Utrecht, The Netherlands. She went on to receive her Diploma Pharmaceutical Medicine (DPM) from Universite Libre de Bruxelles. After transferring to the United States, Dr. Kremer completed the Executive MBA program at New York University’s Leonard N. Stern School of Business.
Senior Director, Global Medical Affairs / AstraZeneca
Dr. Ogün Sazova has graduated Istanbul University Faculty of Medicine and has a specialization degree for family medicine. After spending 5 years in clinical and research setting, he joined pharmaceutical industry in 2003 and worked in local medical and commercial roles before joining AstraZeneca (AZ) Turkey as the Head of Primary Care Medical Affairs. In this role, Ogün has built the MSL function in AZ Turkey amongst other medical affairs deliverables.
In 2009, Ogün moved to EU regional organization in Brussels and was the EU Medical Affairs Director for Cardiovascular Diseases. In 2012, he was appointed as the Global Nominated Signatory Practice Director in Global Medical Excellence group, and moved to London with his family. In this role, Ogün has set standards for Nominated Signatory operations worldwide, including risk & control framework, training, accreditation, and many examples of simplification. After this role, Ogün has taken over the lead of the Global Medical Academy and established it as one of the important tools in AZ to drive world-class scientific engagements by medical teams in the countries.
After working in Turkey, Germany and Belgium, Ogün now lives in the UK and works as the Enterprise External Scientific Engagement Lead in AZ Global Medical Affairs.
Vice President, Head of Global Medical Affairs / Novartis/ Avexis
Dr. Ramin Farhood is a Senior Level Biotechnology and Pharmaceutical Executive with 20 years of experience in scientific and strategic operational leadership in Global Medical Affairs (GMA), Scientific Affairs and Shared Medical Excellence. His expertise is vast in building scalable world-wide organizational and operational capabilities of Medical Affairs while driving efficiencies and implementing best practices. His diverse therapeutic expertise spans across Oncology, Hematology, Immunology, and Ophthalmology.
Currently, Dr. Farhood is the Vice President, Head of Global Medical Affairs at AveXis. In this role, he is a key member of the senior leadership team accountable for World-Wide Medical Affairs organization. Previously, he served as the VP, Head of External Scientific Affairs for Shire who recently acquired Baxalta in July 2016. In this role, he was responsible for developing a strategic vision for the Medical Affairs Evidence Generation group. His accountabilities encompass Medical Evidence Generation, Continuum of Access to Medicines, Laboratory Services, Home Therapy Support, HCP Engagement Support & Educational Grants, Investigator Initiated Trials (IITs) and Professional Society Engagement Support. Here, he has been an inspirational leader who serves as a strategic business partner, cultural and change steward and operational expert.
Prior to his current role, he served as the Head of Medical Operations and Strategy at Baxalta. During his tenure, he built a flexible and scalable world-wide organizational and operational capability of Medical Affairs via centralizing common medical and operational activities globally with centralized hubs in the regions, driving efficiencies and productivities, and sharing and implementing best practices.
Earlier in his career, as Head of Global & US Medical Affairs for Immunology Franchise at Baxter, he was responsible for overseeing the Immunology franchise, leading the development and implementation of medical and commercial strategies, Life-Cycle Management and launch of products. This experience included diverse disciplines of medical and commercialization of drugs, such as leading medical communications and publications, Investigated Initiated Trials (IITs), educational activities (CMEs/IMEs), field-based medical teams (MSLs) and field-based outcome research teams (MSOLs), compliance and SOP developments.
Dr. Farhood acquired his Doctorate in Pharmacy from the University of Southern California (USC) and an MBA from the University of California, Los Angeles (UCLA). He currently holds the position of Adjunct Professor at the School of Pharmacy at USC and Keck Graduate Institute (KGI) and has established industry Post-Doctorate Fellowship programs in the US. He has been selected as the recipient of the Alumnus of the Year Award for his distinguished career, leadership, and contribution to the profession as a clinician, educator, and executive.
Dr. Farhood’s vast skills and knowledge have made him a leading and sought after expert in the industry. He is a frequent speaker at executive medical leadership forums and trainings, has multiple publications in industry journals and has written book chapters related to Medical Affairs. He is on the Board of Directors for the Medical Affairs Professional Society (MAPS) and holds membership in numerous professional affiliations
Brindan Suresh is a Partner with McKinsey and Company based in London. He leads the pharmaceutical practice in the UK & Ireland and co-leads the Firm’s work in Medical Affairs globally. He works primarily with innovator pharmaceutical and medical-device companies in Asia, Europe, and the United States. Brindan focuses on strategy and organizational issues across R&D, Medical and Commercial. He works on a range of topics, helping organizations take a more “science forward, patient back” perspective. This includes recent work helping to set the long-range strategies of a number of clients, the application of digital and analytics across the pharmaceutical value chain, and applying our latest thinking on maximizing talent and leadership across the industry. Brindan convenes our cross-industry medical-affairs leader roundtable and regularly presents our insights externally on innovation-related topics. He also worked as a physician before joining McKinsey, and holds an MD and JD.
Global Medical Lead – Orphan Diseases / Vifor Pharma
Peter Rutherford is Global Medical Lead for Renal Rare Disease at Vifor Pharma in Zurich, CH. He qualified in Medicine at the University of Newcastle upon Tyne, UK and completed postgraduate medical training to obtain MRCP in 1989. He entered an academic training pathway in Nephrology with an MRC Training Fellowship allowing him to complete a PhD in cell physiology as well as completing clinical training in Nephrology and Internal Medicine. He was then an MRC Travelling Fellow at Yale University School of Medicine gaining additional academic experience in molecular biology.
After return to the UK as Lecturer in Medicine at the Unversity of Newcastle, he was appointed as Senior Lecturer in Nephrology at the University of Wales College of Medicine and Consultant Nephrologist. In this role, he combined clinical practice in delivering a full range of nephrology services with academic work. Peter then developed expertise as a clinical leader in the hospital and became the Medical Director of a combined acute, community and mental health NHS organization leading on patient safety, clinical effectiveness, service improvement and research. In addition he was a Clinical advisor at NICE and chaired their Guidelines Review Panel until he joined Pharma in 2007.
From 2007 to 2015 he was Medical Director Renal for Europe, Middle East and Africa at Baxter Healthcare – being responsible for all aspects of Medical Affairs activities across the region. He worked on research projects in patient support, decision making and education as well as new product development for home dialysis. From 2015 to 2017 he was Head of Integrated Market Access at Quintiles in Europe and Emerging Markets – supporting small and large Pharma and emerging biotech companies with medical affairs, medical communications, market access and patient centric services. Focused on launch brands, Peter support a range of companies across a range of therapeutic areas. Since joining Vifor Pharma, he is back on home ground in Nephrology but working in systemic diseases affecting every organ system.
Dr. Maru is an academic physician, Neuroimmunologist and health economist with extensive global experience in clinical research and development, translational medicine, health economics, real-world evidence, and medical affairs.
With a specialty in economic modeling and real-world evidence generation, Benit’s scientific and industry career has primarily focused around neurology, neuroimmunology, immuno/haemato- oncology, and biological therapies for inflammatory diseases, nephrology, dermatology and rheumatology, and rare/ultra-rare disease.
Former Vice President, Global Medical Excellence Global Medical Affairs / AstraZeneca
Mary Alice Dwyer, PharmD, is an experienced Medical Affairs leader with expertise and proven track record in creating transformational change initiatives, building and leading effective Medical Affairs teams, and implementing patient-centric practices. An enterprise-wide and global leader whose achievements include developing and leading a Medical Excellence function that elevated Medical Affairs deliverables through global, regional, and local medical partnerships while ensuring strong governance processes. Mary Alice has led patient centricity practices, which have established patient networks that provide insight and impact drug development.
Most recently, Mary Alice was Vice President of Global Medical Excellence (GME) at AstraZeneca. She led the GME organization which included Global Publications, Global MSL Excellence, Global Nominated Signatory, the Medical Academy, Medical Resources, and Patient Centricity (PaCe). In this role, she led the partnership between GME and Medical in the regions and countries to build and sustain medical capabilities, skills and knowledge. Mary Alice first joined AstraZeneca in 2004 as the Executive Director of Scientific Affairs and was subsequently promoted to Vice President of Medical Affairs in the US. She has also led scientific and medical teams at Takeda, Pharmacia, and Searle. She previously worked in clinical drug development at Hoffmann-LaRoche and Glaxo.
Mary Alice is currently the Principal/Consultant with Medical Innovation and Insights, providing Medical Affairs consulting services.
Dr. João Dias is an honors graduate of the University of Helsinki. He received his Licentiate/MSc in biochemistry from the Universities of Porto, Portugal and Wageningen, the Netherlands; and his PhD studies in Immuno-Oncology and Gene Therapy at Helsinki University Central Hospital and Helsinki University, faculty of Medicine.
He is currently responsible for international medical affairs and clinical development for the medical devices and diagnostics portfolio at Haemonetics which includes Hemostasis Management, Cell Salvage and Transfusion Management products. Prior to this role, João had a variety of roles of increasing responsibility in the areas of both market access and medical marketing.
He has authored several peer-reviewed publications and white papers in the fields of Hemostasis, Patient Blood Management, Immuno-Oncology, Gene Therapy, Hematology, and Molecular Biology.
Prior to his tenure at Haemonetics, João worked as a scientist in the development of new products in Cancer Gene Therapy and served as a Life Sciences Consultant working together with multiple global life-science companies.”
Senior Vice President, Head of Global Medical Affairs Oncology / Eisai / (Former 16'-17' MAPS President)
Dr. Kirk Shepard is the 2016-2017 President of the Medical Affairs Professional Society and has more than 25 years of experience in the pharmaceutical industry. He is a board-certified medical oncologist and hematologist physician. He is currently Senior Vice President, Head of Global Medical Affairs Oncology at Eisai Pharmaceutical Company.
Dr. Shepard’s experience in multiple therapeutic areas includes operational and strategic product development from Phases I through IV and the diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, health economics & outcomes research & patient access, data generation, field-based medical teams (MSLs), PV/safety, medical communication & publications, patient advocacy, and public relations. In 2015, he was selected as one of the 100 Most Inspiring People in the Pharmaceutical Industry (PharmaVOICE).
Before his pharmaceutical career, Dr. Shepard served as a staff physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic Foundation, where he supervised numerous studies in oncology and symptom control. He has more than 50 medical publications in journals and books. Dr. Shepard earned his bachelor’s degree from Cornell University in Ithaca, NY, and his medical degree from the University of Cincinnati Medical School in Cincinnati, OH. He completed both his internship and residency in internal medicine at Case Western Reserve University in Cleveland, OH, and fellowships in hematology and oncology at the University of Chicago Hospitals and Clinics in Chicago, IL.
Shauna brings more than a decade of extensive experience across the pharmaceutical, biotech, medical device and research markets. She has a passion for innovation and driving impact and has demonstrated that success through her strong collaborations and supportive partnerships across the healthcare continuum. As the Senior VP of Strategic Accounts at MedEvoke, Shauna is a driven leader providing strategic support and best practices to the organization’s partners and clients. Using her extensive experience and knowledge of the market, clinical development and launch excellence, Shauna employs creative thinking, combined with data insight to deliver unique and strategic solutions. Shauna received her bachelor of science in biology from Salisbury University, in Maryland, with a focus on premed studies and genetic research. She also holds a second bachelor’s degree in psychology from Towson University and earned her MBA degree with a specialization in management and marketing.
Anna Walz is a 25-year veteran in the pharmaceutical industry and is the CEO of MedEvoke which she founded in 1999. MedEvoke is dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges. Anna, who often speaks on the topics of metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization and MIT. She is also actively involved in her community, serving as a Chairman of the Board of Trustees for Hunterdon Regional Community Health, the Hunterdon Healthcare System, and is an active member the Hunterdon Medical Center Strategic Planning Committee. Outside of her professional achievements, Anna earned her black belt in Shito Ru karate, is multiple marathon runner, and enjoys weightlifting at her local crossfit gym.
Vice President, Global Ethics & Compliance / Ipsen Pharma
Giota is a senior professional with over eleven years of experience in Ethics & Compliance and Internal Controls in multinational pharmaceutical companies.
In March 2015, Giota joined Ipsen and since then she has been responsible for the development and enhancement of the Global Internal Ethics & Compliance Program and she has been the Ethics & Compliance Officer for the Global Teams reporting to the Ipsen’s Chief Ethics & Compliance Officer. In February 2016, in addition to her global responsibilities, Giota also took over the oversight of the Ipsen China Ethics & Compliance Program’s evolution and in January 2018, France has been added under her oversight.
Previously, Giota was Country Compliance & Ethics Officer for various European countries and Contributor to the European Compliance & Ethics Program in Bristol-Myers Squibb based in Paris and Athens and earlier, she held various positions in Business Controls in the same company based in Athens.
She received a university degree on Management Science & Technology from the Athens University of Economics and Business and completed the Sciences Po European Healthcare Compliance, Ethics and Regulation Programme and the Insead Healthcare Compliance Implementation Leadership Programme – Part II.
Giota speaks Greek, English and French and she is member of the ETHICS Association.
Tony has over 30 years of experience creating and delivering analytical products and services. In his prior career in the U.S. intelligence community, he directed intelligence operations in various strategic analysis organizations in the US and abroad. Subsequently, Tony used his insight to apply intelligence methodologies to pharmaceutical industry problems. Over the past decade, he has developed the leading-edge technologies that are now Voxx Analytics, creating easy-use advanced analytics for engagement-related challenges. Tony has an MS from National Intelligence University and an MBA from the Peter F. Drucker School of Business.
Lori Mouser is the Global Head of Medical Science Liaisons (MSL) at F. Hoffman La Roche. She champions the success of MSLs to advance medicine through their engagements with healthcare providers. Leading MSL teams for over 17 years, Lori brings the experience from a range of therapeutic areas. She has US and Global exposure and operates with a commitment to creating solutions through collaboration.
Lori’s first MSL position was at Aventis (now Sanofi) where she quickly gravitated to leading MSL teams during her 12 years with the company. Joining the Roche organization at Genentech in 2012, Lori ultimately had responsibility for the national US Oncology MSL and field leadership teams. Building upon that background, Lori expanded her scope in 2017 to serve the Roche global organization in her current role.
Lori holds a Doctor of Pharmacy Degree and prior to the pharmaceutical industry, she had an
academic career as an Associate Professor in Clinical Pharmacy at Washington State University.
Senior Director, Insights and Training Global Lead Medical Communications, Medical Affairs/ Astellas
Milana Zivkov is a Senior Director, Insights & Training Global Lead, Medical Affairs, Astellas, located in Northbrook, IL, USA. She has been with Astellas since 2013 in various roles of increasing responsibility within Scientific Publications in Medical Affairs. She was instrumental in establishing Scientific Publications as a strategic partner across M & D, and from 01 July 2018, in new her new role, she is responsible for setting up Insights & Training function within Astellas. She has MD and MSc (Clinical Pharmacology) degrees from University of Belgrade Medical School, and is a fully trained neuropsychiatrist. Following a career in clinical psychiatry, Milana has worked in the pharmaceutical industry for more than 20 years holding positions in various Medical Affairs.
Strategy consultant in Life Sciences for 14 years, Casper has extensive experience in defining and implementing transformational strategies in Medical Affairs, Market Access, Commercial and Value-based Healthcare. He is the sponsor of the Medical Affairs Centre of Excellence in Vintura. Casper is a strong believer in co-creation and collaboration with multiple healthcare stakeholders to reach the best outcomes for patients.
Natalia is a Life Science Strategy Consultant for 4 years. Natalia has experience in market entry, market access and Medical transformation projects. As the Vintura co-leader of the Medical Affairs Centre of Excellence, she is mainly focusing on shifting the mindset towards more value based discussions and solutions, incl. capabilities building and development. She believes that,
when connecting different competencies, the objectives are easier and faster achieved.
Asia is passionate about learning & development and particularly enjoys watching others develop and grow with an ultimate aim of enhancing individual, team and organisational effectiveness. With a career that started 17 years ago in the Pharmaceutical Industry having gained an honours degree in Biological Sciences, Asia has spent the last 3 years with Amplity Health providing expertise and delivering value to Medical Affairs teams across the globe. Her background in sales and L&D working for a number of highly innovative Pharmaceutical companies has given her insight into the challenges faced by the Industry today.
In her role as Account Director for Amplity Health Asia works closely with various stakeholders across the Pharma spectrum to understand the needs of their Medical Affairs teams and create solutions to help drive and achieve Medical outcomes. She has expertise in working with MSLs, Medical Managers and Medical Leadership teams, as well as working with clients to improve cross-functional working across the organisation.
Asia has used her expertise in blended learning to incorporate various methods of intervention into learning programmes, making use of remote and virtual platforms to enhance learner engagement and experience. She is an experienced L&D Professional; a trainer, facilitator and a qualified Licensed Business Practitioner of NLP, and her focus is on communication and building relationships. She likes to challenge people to assess their own attitudes and behaviour, and those of others, to help develop the skills necessary to ensure lasting relationships, and, in turn, high performance.
Lead Facilitator and Executive Coach/ Amplity Health
Fiona is curious about people and about business. She is Passionate about helping people connect with their spirit in both a professional and personal context – inspiring the leader within to shine. Fiona has been part of Tardis Medical since the company’s inception and has been an integral member of the team ever since. Prior to that she had a successful career in the pharmaceutical industry with over 15 years working in a variety of sales, management, training, coaching and Organisational Development roles.
Fiona has experience across the whole Tardis Medical portfolio and has developed or been instrumental in the design of many programmes.
Consistent feedback from clients is that Fiona understands the dynamics and the politics of senior executive teams and is able to navigate a path of empathy and challenge. She manages to hold the space for people to express what the real issues are and ensure that people learn and grow. By recognising and appreciating the capability of individuals and teams, Fiona will choose the appropriate intervention, whether that be informing, confronting or catalytic.
Fiona works closely with clients across the full spectrum of the pharmaceutical industry across a range of different disease areas in both pre and post licence phases. She understands why good governance is important from a strategic perspective and helps people find what they need so they can operate with confidence and credibility when interacting with stakeholders.
As well as being an accredited MBTI Facilitator and an accredited Change Management Facilitator, Fiona is a qualified NLP Practitioner and a certified Performance Coach (Newcastle University). She is also a Senior Yoga Teacher (RYT 500 Yoga Alliance) and studied Mindfulness at Oxford. It is because of this breadth of skills and experience that Fiona is able to be versatile and flexible when working with individuals and groups.
Tarun has over 27 years of experience and has been associated with Indegene for the past 17+ years. He leads the technology domain at Indegene and his responsibilities include development of technology-based solutions focused on the healthcare industry. His strengths lie in his technological expertise and business acumen, which help in developing various platforms and next-generation IT solutions.
Sameer heads a business unit at Indegene focusing on services to Medical Affairs organizations in life sciences companies. Sameer drives the overall P&L through sales and marketing efforts, capability building, innovation and delivery. He is also setting up a new service line (value proposition, capability mix, resourcing, external partnership, key client wins) to increase market penetration and drive business growth. He is also the global client partner for several of the top accounts at Indegene. He is responsible for managing a team of professionals based in multiple geographies with a mandate to grow Indegene’s business across service lines.
Sameer has over twenty two years of experience both in the pharmaceutical industry as well as on the services side. Prior to joining Indegene, Sameer has served a variety of leadership roles in companies like GlaxoSmithKline and Sudler & Hennessey. His expertise lies in building long-term strategic client relationships; developing programs to address specific business problems; and effectively executing against set objectives.
Sameer is an MBA in Marketing with a Bachelor’s degree in Chemical Technology
Vice President, Global Head of Medical Strategy and Innovation/ Allergan
Kevin is a UK qualified pharmacist with nearly 15 years experience in medical affairs internationally. He has grown his career within medical affairs from an MSL role within the UK to building an International team of 200. Kevin worked on the integration and building of a new Medical department following the acquisition of Allergan by Actavis and on the separation of a Medical department following the divestiture of the Allergan generics business to Teva. Most recently Kevin has been working on bold proposals to reshape how Medical Affairs will adapt to the changing healthcare and consumer markets as peoples’ expectations rapidly evolve.